Clinical benefit of gemcitabine-cisplatin in advanced non-small cell lung cancer elderly patients

Anticancer Research

Volumn 22, Issue 2 B, 2002, Pages 1053-1059

  Lippe, Paolo ^a   Silva, Rosa R ^a   Giuliodori, Luciano ^a   Monterubbianesi, Maria C ^a   Mattioli, Rodolfo ^a   Massacesi, Cristian ^a   Cascinu, Stefano ^a   Tummarello, Diego ^a   Cellerino, Riccardo ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

Chemotherapy; Cisplatin; Clinical benefit; Elderly; Gemcitabine; Non small cell lung cancer

Indexed keywords

CISPLATIN; GEMCITABINE;

AGED; AGING; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DRUG RESPONSE; DYSPNEA; FEMALE; HEMOPTYSIS; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PAIN; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL TIME; SYMPTOMATOLOGY; THROMBOCYTOPENIA; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROSPECTIVE STUDIES;

EID: 0036322634     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Chemotherapy can prolong survival in patients with advanced non/small cell lung cancer. Report of a Canadian multicenter randomized trial
2. Cisplatin, cyclophosphamide, mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small cell lung cancer
3. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
4. Polychemotherapy in advanced non-small cell lung cancer-a meta-analysis
5. Chemotherapy for advanced non-small cell lung cancer-how much benefit is enough?
6. Symptom relief with moderate dose chemotherapy (mitomycin C, vinblastine and cisplatin) in advanced non-small cell lung cancer
7. Symptomatic, stage IV, non-small-cell-lung cancer (NSCLC): Response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C
8. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two stage phase II study
9. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer
10. Weekly gemcitabine and cisplatin in advanced non-small cell lung cancer: A phase II study
11. Advanced non-small cell lung cancer (ANSCLC) in the elderly: Effective and well tolerated weekly gemcitabine (GEM) and cisplatin (CDDP) regimen
12. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma
13. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer
14. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer
15. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
16. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
17. Multicenter phase II study of capecitabine in paclitaxel -refractory metastatic breast cancer
18. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: A phase II trial
19. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer
20. Nonparametric estimation from incomplete observations
21. Assessment and management of breathlessness
22. New guidelines to evaluate the response to treatment in solid tumors
23. Second line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based with advanced non-small cell lung cancer
24. Gemcitabine as single agent in the treatment of elderly patients with advanced non-small cell lung cancer
25. New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non-small cell lung cancer